Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis signs licensing agreement for cancer therapy

Sanofi-Aventis signs licensing agreement for cancer therapy

28th March 2007

Sanofi-Aventis has announced that it has entered into a global licensing agreement with UK-based firm Oxford BioMedical for the development and commercialisation of TroVax for the prevention and treatment of cancer.

According to the terms of the agreement, Sanofi-Aventis will pay Oxford BioMedical an initial payment of 29 million euros (19.7 million pounds) with an additional 19 million euros paid over the course of the Trist study and further payments of up to 518 million euros made depending on developmental progress.

Sanofi-Aventis will be responsible for the global sales and commercialisation of the compounds and will fund all activities relating to research, development and regulatory applications for the drug.

TroVax is a cancer immunotherapy drug that targets tumour antigen 5T4 present in a number of solid-tumours and correlated with poor prognosis in patients. The drug stimulates the body to produce an anti-5T4 immune response to destroy tumour cells.

Professor Alan Kingsman, chief executive of Oxford BioMedica, said: “We are delighted to have Sanofi-Aventis as our partner for TroVax given their broad expertise, experience and resources in oncology and their long-standing world-class research and development capabilities in cancer immunology.”

He added that Oxford BioMedica would look forward to its collaboration with the firm to provide new treatment options for cancer patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.